CLINICAL TRIALS PROFILE FOR OMONTYS
✉ Email this page to a colleague
All Clinical Trials for omontys
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00097747 ↗ | Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers | Completed | Affymax | Phase 1 | 2004-08-01 | The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and minimum pharmacologically active dose of peginesatide in Healthy Volunteers. |
| NCT00109291 ↗ | Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease | Terminated | Affymax | Phase 2 | 2005-03-01 | To evaluate the safety profile of single intravenous (IV) dose levels of peginesatide in participants with chronic kidney disease(CKD) not on dialysis. |
| NCT00228436 ↗ | Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients | Completed | Affymax | Phase 2 | 2005-09-01 | The purpose of this study was to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple subcutaneous injections of peginesatide in participants with chronic kidney disease (CKD) not on dialysis who had not received erythropoiesis stimulating agent (ESA) treatment. |
| NCT00228449 ↗ | Peginesatide for Anemia in Chronic Hemodialysis Patients | Completed | Affymax | Phase 2 | 2005-07-01 | The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple intravenous doses of peginesatide in participants with chronic kidney disease (CKD) who are on hemodialysis. |
| NCT00272662 ↗ | Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy | Completed | Affymax | Phase 2 | 2006-01-01 | The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple subcutaneously administered injections of peginesatide in anemic cancer participants receiving chemotherapy. |
| NCT00314795 ↗ | Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease | Completed | Takeda | Phase 2 | 2006-04-06 | The purpose of this study is to evaluate the ability of peginesatide (AF37702) to increase and maintain increased hemoglobin levels in participants with chronic kidney disease (CKD) (either not on dialysis, receiving regular hemodialysis or peritoneal dialysis, or following renal transplant) with confirmed antibody-mediated pure red cell aplasia (PRCA). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for omontys
Condition Name
Clinical Trial Locations for omontys
Trials by Country
Clinical Trial Progress for omontys
Clinical Trial Phase
Clinical Trial Sponsors for omontys
Sponsor Name
